Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Wino115on Sep 25, 2020 9:07pm

208 Views

Post# 31624480

RE:RE:RE:RE:Scientific Panel - 6 Docs

Get used to it GiGiGi. The reason we are all anticipating solid, fundamental, altering news about doing a Phase 3 in NASh and a Phase 1 in oncology. Biotechs need solid future developments under their belt with approvals as catalytic events that get them to the next level. News will flow with those trials and open up much larger markets. That's how you create value. But we need to get there. Right now it's an ignored microcap where $200,000 can move it 10%. That's not a serious investment case for larger guys. It will come if they execute positively, but that's the wait.
Buckle your seatbelt and be patient GiGi.